Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05066165 · ClinicalTrials.gov registry record · Phase 1
Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia
A Phase 1 study, sponsored by Intellia Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05066165 is a Phase 1 study that was terminated before completion, run by Intellia Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT05066165, a Phase 1 study, was terminated before completion, sponsored by Intellia Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will be conducted to evaluate the safety, tolerability, cellular kinetics (CK), activity, and pharmacodynamics (PD) of NTLA-5001 in participants with Acute Myeloid Leukemia (AML).
Interventions
- GENETIC Arm 1: NTLA-5001
- GENETIC Arm 2: NTLA-5001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-12-17 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05066165
The ClinicalTrials.gov registry entry for NCT05066165 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intellia Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Arm 1: NTLA-5001 is the first listed.
NCT05066165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05066165 about?
NCT05066165 is a clinical study titled "Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia". This study will be conducted to evaluate the safety, tolerability, cellular kinetics (CK), activity, and pharmacodynamics (PD) of NTLA-5001 in participants with Acute Myeloid Leukemia (AML).
What is the current status of trial NCT05066165?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-12-17. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT05066165?
The interventions under investigation include: Arm 1: NTLA-5001 (GENETIC), Arm 2: NTLA-5001 (GENETIC).
Who is sponsoring clinical trial NCT05066165?
This trial is sponsored by Intellia Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.